US10576066B2ActiveUtilityA9

Histone deacetylase as a modulator of PDLI expression and activity

70
Assignee: H LEE MOFFITT CANCER CT & RESPriority: Apr 6, 2014Filed: Jun 5, 2018Granted: Mar 3, 2020
Est. expiryApr 6, 2034(~7.7 yrs left)· nominal 20-yr term from priority
Inventors:Alejandro V. VillagraEduardo M. Sotomayor
A61K 31/505A61K 31/437A61K 31/4045A61K 31/17A61K 31/422A61K 31/506A61K 45/06A61K 31/4406A61K 31/416
70
PatentIndex Score
0
Cited by
2
References
4
Claims

Abstract

Disclosed herein is a method for modulating Program Death Receptor Ligand 1 (PDL1) in a cancer cell, comprising contacting the cell with a composition comprising a histone deacetylase (HDAC) inhibitor. Also disclosed is a method for treating a tumor in a subject, comprising administering to the subject a therapeutically effective amount of a composition comprising a histone deacetylase (HDAC) inhibitor and a composition comprising a therapeutically effective amount of a Program Death Receptor Ligand 1 (PDL1) inhibitor, a Programmed Death 1 receptor (PD1) inhibitor, or a combination thereof.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
       1. A method for modulating Program Death Receptor Ligand 1 (PDL1) in a cancer cell, comprising contacting the cell with a composition comprising a histone deacetylase (HDAC) inhibitor. 
     
     
       2. The method  claim 1 , wherein the HDAC inhibitor comprises a selective inhibitor of histone deacetylase 6 (HDAC6). 
     
     
       3. The method  claim 2 , wherein the HDAC6 inhibitor is selected from the group consisting of ACY-1215, Tubacin, Tubastatin A, ST-3-06, and ST-2-92. 
     
     
       4. The method of  claim 1 , wherein the HDAC inhibitor comprises a pan inhibitor, a class I HDAC inhibitor, or a combination thereof.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.